Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamid (asta z 7557)

Tucker W. LeBien; Janet M. Anderson; Daniel A. Vallera; Fatih M. Uckun

doi:10.1016/0145-2126(86)90036-6

Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamid (asta z 7557)

Tucker W. LeBien, Janet M. Anderson, Daniel A. Vallera, Fatih M. Uckun

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Studies were undertaken to examine the efficacy of combining monoclonal antibodies BA-1, BA-2, BA-3 + complement with a stabilized derivative of cyclophosphamide (mafosfamid) for elimination of leukemic cell line clonogenic cells. In a series of experiments conducted with leukemic cell lines a combination of two cycles of treatment with BA-1, 2, 3 + complement combined with 25 μg/ml^-1 mafosfamid was superior to either modality alone in killing clonogenic leukemic cells. Identical treatment of normal bone marrow had no effect on the monopotent stem cells CFU-E and CFU-GM, or the pluripotent stem cell CFU-MIX, but some inhibition of the monopotent stem cell CFU-MK did occur. These results suggest that consideration be given to incorporation of BA-1, 2, 3 + complement and mafosfamid combination treatment in autologous bone marrow transplantation for acute lymphoblastic leukemia.

Original language	English (US)
Pages (from-to)	139-143
Number of pages	5
Journal	Leukemia research
Volume	10
Issue number	2
DOIs	https://doi.org/10.1016/0145-2126(86)90036-6
State	Published - 1986

Bibliographical note

Funding Information:
*This work was supported by grants CA-21737, CA-31685, and CA-36725 from the National Institutes of Health, grant IM-380 from the American Cancer Society, and a grant from the Prudential Insurance Company of America. T.W.L. and D.A.V. are Scholars of the Leukemia Society of America.

Keywords

Autologous bone marrow transplantation
mafosfamid
monoclonal antibody + complement

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/0145-2126(86)90036-6

OpenUrl availability

Full text

Cite this

Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamid (asta z 7557). / LeBien, Tucker W.; Anderson, Janet M.; Vallera, Daniel A. et al.
In: Leukemia research, Vol. 10, No. 2, 1986, p. 139-143.

Research output: Contribution to journal › Article › peer-review

@article{2c76c03411874a758401480d47a4c984,

title = "Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamid (asta z 7557)",

abstract = "Studies were undertaken to examine the efficacy of combining monoclonal antibodies BA-1, BA-2, BA-3 + complement with a stabilized derivative of cyclophosphamide (mafosfamid) for elimination of leukemic cell line clonogenic cells. In a series of experiments conducted with leukemic cell lines a combination of two cycles of treatment with BA-1, 2, 3 + complement combined with 25 μg/ml-1 mafosfamid was superior to either modality alone in killing clonogenic leukemic cells. Identical treatment of normal bone marrow had no effect on the monopotent stem cells CFU-E and CFU-GM, or the pluripotent stem cell CFU-MIX, but some inhibition of the monopotent stem cell CFU-MK did occur. These results suggest that consideration be given to incorporation of BA-1, 2, 3 + complement and mafosfamid combination treatment in autologous bone marrow transplantation for acute lymphoblastic leukemia.",

keywords = "Autologous bone marrow transplantation, mafosfamid, monoclonal antibody + complement",

author = "LeBien, {Tucker W.} and Anderson, {Janet M.} and Vallera, {Daniel A.} and Uckun, {Fatih M.}",

note = "Funding Information: *This work was supported by grants CA-21737, CA-31685, and CA-36725 from the National Institutes of Health, grant IM-380 from the American Cancer Society, and a grant from the Prudential Insurance Company of America. T.W.L. and D.A.V. are Scholars of the Leukemia Society of America.",

year = "1986",

doi = "10.1016/0145-2126(86)90036-6",

language = "English (US)",

volume = "10",

pages = "139--143",

journal = "Leukemia research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamid (asta z 7557)

AU - LeBien, Tucker W.

AU - Anderson, Janet M.

AU - Vallera, Daniel A.

AU - Uckun, Fatih M.

N1 - Funding Information: *This work was supported by grants CA-21737, CA-31685, and CA-36725 from the National Institutes of Health, grant IM-380 from the American Cancer Society, and a grant from the Prudential Insurance Company of America. T.W.L. and D.A.V. are Scholars of the Leukemia Society of America.

PY - 1986

Y1 - 1986

N2 - Studies were undertaken to examine the efficacy of combining monoclonal antibodies BA-1, BA-2, BA-3 + complement with a stabilized derivative of cyclophosphamide (mafosfamid) for elimination of leukemic cell line clonogenic cells. In a series of experiments conducted with leukemic cell lines a combination of two cycles of treatment with BA-1, 2, 3 + complement combined with 25 μg/ml-1 mafosfamid was superior to either modality alone in killing clonogenic leukemic cells. Identical treatment of normal bone marrow had no effect on the monopotent stem cells CFU-E and CFU-GM, or the pluripotent stem cell CFU-MIX, but some inhibition of the monopotent stem cell CFU-MK did occur. These results suggest that consideration be given to incorporation of BA-1, 2, 3 + complement and mafosfamid combination treatment in autologous bone marrow transplantation for acute lymphoblastic leukemia.

AB - Studies were undertaken to examine the efficacy of combining monoclonal antibodies BA-1, BA-2, BA-3 + complement with a stabilized derivative of cyclophosphamide (mafosfamid) for elimination of leukemic cell line clonogenic cells. In a series of experiments conducted with leukemic cell lines a combination of two cycles of treatment with BA-1, 2, 3 + complement combined with 25 μg/ml-1 mafosfamid was superior to either modality alone in killing clonogenic leukemic cells. Identical treatment of normal bone marrow had no effect on the monopotent stem cells CFU-E and CFU-GM, or the pluripotent stem cell CFU-MIX, but some inhibition of the monopotent stem cell CFU-MK did occur. These results suggest that consideration be given to incorporation of BA-1, 2, 3 + complement and mafosfamid combination treatment in autologous bone marrow transplantation for acute lymphoblastic leukemia.

KW - Autologous bone marrow transplantation

KW - mafosfamid

KW - monoclonal antibody + complement

UR - http://www.scopus.com/inward/record.url?scp=0022653442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022653442&partnerID=8YFLogxK

U2 - 10.1016/0145-2126(86)90036-6

DO - 10.1016/0145-2126(86)90036-6

M3 - Article

C2 - 3951251

AN - SCOPUS:0022653442

SN - 0145-2126

VL - 10

SP - 139

EP - 143

JO - Leukemia research

JF - Leukemia research

IS - 2

ER -

Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamid (asta z 7557)

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this